A new study published in Clinical Cancer Research establishes wild-type EGFR as a therapeutically actionable dependency in SMARCB1-deficient renal medullary carcinoma (RMC) and reports the clinical activity of panitumumab-based therapy in a large registry cohort assembled for this ultra-rare kidney cancer. All 11 RMC tumors evaluated by CLIA-certified immunohistochemistry showed membranous EGFR in 100% of tumor cells (median H-score 300), and integrated RNA- and ChIP-sequencing revealed that RMC activates the EGFR locus epigenetically — through enhancer and promoter reprogramming rather than mutation or amplification — while simultaneously switching its ligand repertoire away from EGF (log2FC −8.6) toward epiregulin (+6.3) and amphiregulin (+6.2), which share a common reprogrammed enhancer landscape on chromosome 4. This dependency proved uncoupled from SMARCB1 loss itself: RMC cell lines expressed higher EGFR than epithelioid sarcoma or malignant rhabdoid tumor lines, EGFR H-scores were far higher in RMC than in a 36-case epithelioid sarcoma tissue microarray (median 300 vs 20, P=1.1×10⁻⁶), and tetracycline-induced re-expression of SMARCB1 did not reduce EGFR in any lineage tested. Because wild-type EGFR responds to extracellular antibody blockade rather than to the kinase inhibitors effective against mutant EGFR, panitumumab markedly outperformed erlotinib in RMC xenografts, rapidly suppressed AKT and ERK1/2 signaling, and routed EGFR into LAMP1-positive lysosomes, producing a predominantly cytostatic effect — reduced Ki67 without induction of cleaved caspase-3 or cleaved PARP — accompanied by extensive tumor fibrosis and hyalinization. In a multi-national registry of 26 heavily pretreated patients treated at ten centers across the United States, Canada, and Germany between 2022 and 2025 (96% prior platinum, 89% stage IV at diagnosis), panitumumab-based therapy achieved an objective response rate of 53.9% including 15.4% complete responses, with median progression-free survival of 5.8 months and median overall survival of 9.5 months; toxicity was dominated by grade 1–2 acneiform rash (80.8%), with no treatment-related deaths. These non-randomized registry data provide a biological and clinical rationale for further validation.